EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir

Karen Anbro Gammeltoft, Yuyong Zhou iD, Line Abildgaard Ryberg, Long V Pham, Alekxander Binderup, Carlos Rene Duarte Hernandez, Anna Offersgaard iD, Ulrik Fahnøe, Günther Herbert Johannes Peters iD, Santseharay Ramirez, Jens Bukh iD, Judith Margarete Gottwein iD

Viruses · 2023

DOI: 10.3390/v15091970 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2023. Verfasst von Karen Anbro Gammeltoft und 11 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Kettegård Alle 30, 2650 Hvidovre…. Hauptthemen laut MEDLINE: COVID-19, Hepatitis C, Chronic, Anti-Infective Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Candys Foundation, China Scholarship Council, Amager and Hvidovre Hospital Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nirmatrelvir, which targets the SARS-CoV-2 main protease (Mpro), is the first-in-line drug for prevention and treatment of severe COVID-19, and additional Mpro inhibitors are in development. However, the risk of resistance development threatens the future efficacy of such direct-acting antivirals. To gain knowledge on viral correlates of resistance to Mpro inhibitors, we selected resistant SARS-CoV-2 under treatment with the nirmatrelvir-related protease inhibitor boceprevir. SARS-CoV-2 selected during five escape experiments in VeroE6 cells showed cross-resistance to nirmatrelvir with up to 7.3-fold increased half-maximal effective concentration compared to original SARS-CoV-2, determined in concentration–response experiments. Sequence analysis revealed that escape viruses harbored Mpro substitutions L50F and A173V. For reverse genetic studies, these substitutions were introduced into a cell-culture-infectious SARS-CoV-2 clone. Infectivity titration and analysis of genetic stability of cell-culture-derived engineered SARS-CoV-2 mutants showed that L50F rescued the fitness cost conferred by A173V. In the concentration–response experiments, A173V was the main driver of resistance to boceprevir and nirmatrelvir. Structural analysis of Mpro suggested that A173V can cause resistance by making boceprevir and nirmatrelvir binding less favorable. This study contributes to a comprehensive overview of the resistance profile of the first-in-line COVID-19 treatment nirmatrelvir and can thus inform population monitoring and contribute to pandemic preparedness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Hepatitis C, ChronicAnti-Infective AgentsHumansProtease InhibitorsAntiviral AgentsSARS-CoV-2COVID-19 Drug TreatmentEnzyme InhibitorsLactamsCoronavirus 3C ProteasesProline

Stichwörter der Autor:innen

COVID-19MproMpro inhibitorSARS-CoV-2antiviral resistanceboceprevirnirmatrelvirprotease inhibitor

Substanzen

Protease InhibitorsAntiviral AgentsEnzyme InhibitorsAnti-Infective AgentsLactams3C-like proteinase, SARS-CoV-2Coronavirus 3C ProteasesN-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobut…Proline

Autor:innen und Institutionen

  • Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Kettegård Alle 30, 2650 Hvidovre, Denmark.
  • Copenhagen Hepatitis C Program (CO-HEP), Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark.
  • Department of Chemistry, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.

ORCID-Profile: Yuyong Zhou, Anna Offersgaard, Günther Herbert Johannes Peters, Jens Bukh, Judith Margarete Gottwein

Förderung

  • Candys Foundation
  • China Scholarship Council
  • Amager and Hvidovre Hospital Research Foundation
  • Danish Agency for Science and Higher Education
  • Independent Research Fund Denmark
  • Novo Nordisk Foundation including a Distinguished Investigator Grant
  • Mauritzen la Fontaine Fonden
  • Mauritzen La Fontaine Familiefond

Zitieren

APA

Gammeltoft, K. A., Zhou, Y., Ryberg, L. A., Pham, L. V., Binderup, A., Hernandez, C. R. D., Offersgaard, A., Fahnøe, U., Peters, G. H. J., Ramirez, S., Bukh, J., & Gottwein, J. M. (2023). Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir. Viruses. https://doi.org/10.3390/v15091970

Vancouver

Gammeltoft KA, Zhou Y, Ryberg LA, Pham LV, Binderup A, Hernandez CRD, et al. Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir. Viruses. 2023. doi:10.3390/v15091970

BibTeX
@article{Gammeltoft2023,
  author = {Gammeltoft, Karen Anbro and Zhou, Yuyong and Ryberg, Line Abildgaard and Pham, Long V and Binderup, Alekxander and Hernandez, Carlos Rene Duarte and Offersgaard, Anna and Fahnøe, Ulrik and Peters, Günther Herbert Johannes and Ramirez, Santseharay and Bukh, Jens and Gottwein, Judith Margarete},
  title = {Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15091970}
}
Kostenlos starten →